MedPath

Sham LaserCap vs. LaserCap SD vs. LaserCap HD+

Not Applicable
Recruiting
Conditions
Androgenetic Alopecia
Interventions
Device: Sham LaserCap
Device: LaserCap HD+
Device: LaserCap SD
Registration Number
NCT05365360
Lead Sponsor
University of Arizona
Brief Summary

Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral finasteride1.

In addition to medical therapies, FDA-cleared medical devices are now utilized for the treatment of AGA as of 20072. These devices, termed low level laser therapy (LLLT), come in multiple forms including combs, helmets and sports cap wearable devices2. These home-use, wearable devices utilize the \~650 nm wavelength laser light to stimulate the hair follicle mitochondria and thereby promote hair growth, a process termed "photobiomodulation"3.

Recent meta-analyses investigating photobiomodulation and LLLT for AGA have noted an increase in fluence or energy delivered per cm is associated with increased hair density3. However, randomized control trials (RCT) with direct comparison of LLLT devices of different fluences has yet to be performed. Accordingly, in the present study we aim to investigate if increasing fluence in LLLT devices is associated with increased hair density by comparing sham LaserCap to LaserCap SD (1.15 J/cm2, low fluence) and LaserCap HD+ (3.93 J/cm2, high fluence) in RCT.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sham LaserCapSham LaserCapSham device
Lasercap HD+LaserCap HD+High fluence LLLT
Lasercap SDLaserCap SDLow fluence LLLT
Primary Outcome Measures
NameTimeMethod
Target area total hair count at 26 weeks via phototrichogram26 weeks
Secondary Outcome Measures
NameTimeMethod
Hair growth rate at 26 weeks via phototrichogram26 weeks
Target area terminal hair count at 26 weeks via phototrichogram26 weeks
Physician assessed improvement via global photography at 26 weeks26 weeks
Target area vellus hair count at 26 weeks via phototrichogram26 weeks

Trial Locations

Locations (1)

Banner University Dermatology

🇺🇸

Tucson, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath